{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:14:09Z","timestamp":1779452049303,"version":"3.53.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Roche Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00415-026-13806-0","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:37:41Z","timestamp":1777311461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6746-1034","authenticated-orcid":false,"given":"I. K.","family":"Penner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wiemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Leemhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"1","key":"13806_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12883-016-0639-7","volume":"16","author":"T Ziemssen","year":"2016","unstructured":"Ziemssen T, Kern R, Thomas K (2016) Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol 16(1):124","journal-title":"BMC Neurol"},{"issue":"1","key":"13806_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-116","volume":"10","author":"T Derfuss","year":"2012","unstructured":"Derfuss T (2012) Personalized medicine in multiple sclerosis: hope or reality? BMC Med 10(1):116","journal-title":"BMC Med"},{"issue":"1","key":"13806_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/pn-2024-004228","volume":"25","author":"W Rashid","year":"2025","unstructured":"Rashid W, Ciccarelli O, Leary SM, Arun T, Doshi A, Evangelou N, Ford HL, Hobart J, Jacob S, Muraro PA et al (2025) Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. Pract Neurol 25(1):18\u201324","journal-title":"Pract Neurol"},{"issue":"17","key":"13806_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE et al (2018) Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 90(17):777\u2013788","journal-title":"Neurology"},{"issue":"2","key":"13806_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F et al (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24(2):96\u2013120","journal-title":"Mult Scler"},{"key":"13806_CR6","unstructured":"Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen (S2k-Leitlinie, Version 8.0) AWMF-Registernummer: 030\/050. (Accessed: October 2025) [https:\/\/dgn.org\/leitlinie\/diagnose-und-therapie-der-multiplen-sklerose-neuromyelitis-optica-spektrum-erkrankungen-und-mog-igg-assoziierten-erkrankungen]"},{"issue":"9","key":"13806_CR7","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1093\/brain\/awx185","volume":"140","author":"T Kalincik","year":"2017","unstructured":"Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A et al (2017) Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain 140(9):2426\u20132443","journal-title":"Brain"},{"issue":"8","key":"13806_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080791","volume":"11","author":"A Henschke","year":"2021","unstructured":"Henschke A, Desborough J, Parkinson A, Brunoro C, Fanning V, Lueck C, Brew-Sam N, Br\u00fcstle A, Drew J, Chisholm K et al (2021) Personalizing medicine and technologies to address the experiences and needs of people with multiple sclerosis. J Pers Med 11(8):791","journal-title":"J Pers Med"},{"key":"13806_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419892077","volume":"12","author":"M M\u00e4urer","year":"2019","unstructured":"M\u00e4urer M, Tiel-Wilck K, Oehm E, Richter N, Springer M, Oschmann P, Manzel A, Hieke-Schulz S, Zingler V, Kandenwein JA et al (2019) Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 12:1756286419892077","journal-title":"Ther Adv Neurol Disord"},{"key":"13806_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1765","volume":"350","author":"I Galea","year":"2015","unstructured":"Galea I, Ward-Abel N, Heesen C (2015) Relapse in multiple sclerosis. BMJ 350:h1765","journal-title":"BMJ"},{"key":"13806_CR11","unstructured":"National Institute for Health and Care Excellence: Guidelines. In: Multiple sclerosis in adults: management. edn. London: National Institute for Health and Care Excellence (NICE). Copyright \u00a9 NICE 2022."},{"key":"13806_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0627-1","volume":"14","author":"T Ziemssen","year":"2016","unstructured":"Ziemssen T, Hillert J, Butzkueven H (2016) The importance of collecting structured clinical information on multiple sclerosis. BMC Med 14:81","journal-title":"BMC Med"},{"issue":"2","key":"13806_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"key":"13806_CR14","unstructured":"CDC HRQOL\u201314 \"Healthy Days Measure\". (Accessed: October 2025) [https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/hrqol\/hrqol14_measure.htm]"},{"key":"13806_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241237857","volume":"17","author":"S Papukchieva","year":"2024","unstructured":"Papukchieva S, Stratil AS, Kahn M, Ne\u00df NH, Hollnagel-Schmitz M, Gerencser V, Rustemeier J, Eberl M, Friedrich B, Ziemssen T (2024) Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany. Ther Adv Neurol Disord 17:17562864241237857","journal-title":"Ther Adv Neurol Disord"},{"key":"13806_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105751","volume":"88","author":"S Papukchieva","year":"2024","unstructured":"Papukchieva S, Kim HD, Stratil AS, Magurne E, Jonckheere A, Kahn M, Schneeweiss S, Ziemssen T, Friedrich B (2024) Real-world evidence from Germany and the United States: treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis. Mult Scler Relat Disord 88:105751","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"13806_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/sleep\/33.8.1061","volume":"33","author":"TJ Braley","year":"2010","unstructured":"Braley TJ, Chervin RD (2010) Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep 33(8):1061\u20131067","journal-title":"Sleep"},{"issue":"1","key":"13806_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02396-1","volume":"21","author":"A Oliva Ramirez","year":"2021","unstructured":"Oliva Ramirez A, Keenan A, Kalau O, Worthington E, Cohen L, Singh S (2021) Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol 21(1):468","journal-title":"BMC Neurol"},{"issue":"1","key":"13806_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurop.2024.100181","volume":"5","author":"E Aparicio-Castro","year":"2025","unstructured":"Aparicio-Castro E, Candeliere-Merlicco A, Santa CM, Villaverde-Gonz\u00e1lez R (2025) Association of depression in multiple sclerosis with fatigue, sleep disturbances, disability, and health-related quality of life: outcomes of a cross-sectional study. Neurol Perspect 5(1):100181","journal-title":"Neurol Perspect"},{"key":"13806_CR20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1055\/s-0032-1305248","volume":"39","author":"R Gold","year":"2012","unstructured":"Gold R, Hartung H, Stangel M, Wiendl H, Zipp F, Expertenmeetings T (2012) Therapeutic goals of baseline and escalation therapy for relapsing-remitting multiple sclerosis. Akt Neurol 39:342\u2013350","journal-title":"Akt Neurol"},{"issue":"1\u20132","key":"13806_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/jnr.23955","volume":"95","author":"LC Golden","year":"2017","unstructured":"Golden LC, Voskuhl R (2017) The importance of studying sex differences in disease: the example of multiple sclerosis. J Neurosci Res 95(1\u20132):633\u2013643","journal-title":"J Neurosci Res"},{"issue":"6","key":"13806_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122686","volume":"10","author":"KA Ribbons","year":"2015","unstructured":"Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, Girard M, Grand\u2019Maison F, Hupperts R, Grammond P et al (2015) Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. PLoS ONE 10(6):e0122686","journal-title":"PLoS ONE"},{"key":"13806_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103401","volume":"58","author":"GG Luetic","year":"2022","unstructured":"Luetic GG, Menichini ML, Vrech C, Pappolla A, Patrucco L, Cristiano E, Marrod\u00e1n M, Ysrraelit MC, Fiol M, Correale J et al (2022) Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis? Mult Scler Relat Disord 58:103401","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"13806_CR24","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00415-015-8005-z","volume":"263","author":"R Bove","year":"2016","unstructured":"Bove R, McHenry A, Hellwig K, Houtchens M, Razaz N, Smyth P, Tremlett H, Sadovnick AD, Rintell D (2016) Multiple sclerosis in men: management considerations. J Neurol 263(7):1263\u20131273","journal-title":"J Neurol"},{"key":"13806_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669811","volume":"12","author":"I Voigt","year":"2021","unstructured":"Voigt I, Inojosa H, Dillenseger A, Haase R, Akg\u00fcn K, Ziemssen T (2021) Digital twins for multiple sclerosis. Front Immunol 12:669811","journal-title":"Front Immunol"},{"key":"13806_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106113","volume":"181","author":"JF Catal\u00e0-Senent","year":"2023","unstructured":"Catal\u00e0-Senent JF, Andreu Z, Hidalgo MR, Soler-S\u00e1ez I, Roig FJ, Yanguas-Cas\u00e1s N, Neva-Alejo A, L\u00f3pez-Cerd\u00e1n A, de la Iglesia-Vay\u00e1 M, Stranger BE et al (2023) A deep transcriptome meta-analysis reveals sex differences in multiple sclerosis. Neurobiol Dis 181:106113","journal-title":"Neurobiol Dis"},{"issue":"4","key":"13806_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/1756285616634247","volume":"9","author":"R Haase","year":"2016","unstructured":"Haase R, Kullmann JS, Ziemssen T (2016) Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord 9(4):250\u2013263","journal-title":"Ther Adv Neurol Disord"},{"key":"13806_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/PPA.S452849","volume":"18","author":"O Hoffmann","year":"2024","unstructured":"Hoffmann O, Paul F, Haase R, Kern R, Ziemssen T (2024) Preferences, adherence, and satisfaction: three years of treatment experiences of people with multiple sclerosis. Patient Prefer Adherence 18:455\u2013466","journal-title":"Patient Prefer Adherence"},{"key":"13806_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2147\/PPA.S248272","volume":"14","author":"D Schriefer","year":"2020","unstructured":"Schriefer D, Haase R, Kullmann JS, Ziemssen T (2020) Health-related quality of life and the relationship to treatment satisfaction in patients with multiple sclerosis: insights from a large observational study. Patient Prefer Adherence 14:869\u2013880","journal-title":"Patient Prefer Adherence"},{"key":"13806_CR30","unstructured":"Multiple Scleroisis. (Accessed: October 2025) [https:\/\/www.ninds.nih.gov\/health-information\/disorders\/multiple-sclerosis]"},{"issue":"12","key":"13806_CR31","first-page":"737","volume":"117","author":"J Hao","year":"2017","unstructured":"Hao J, Pitcavage J, Jones JB, Hoegerl C, Graham J (2017) Measuring adherence and outcomes in the treatment of patients with multiple sclerosis. J Am Osteopath Assoc 117(12):737\u2013747","journal-title":"J Am Osteopath Assoc"},{"issue":"1","key":"13806_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12883-024-03594-3","volume":"24","author":"S C\u00e1rdenas-Robledo","year":"2024","unstructured":"C\u00e1rdenas-Robledo S, Arenas-Vargas LE, Arenas RD, Gaspar-Toro JM, Mu\u00f1oz-Rosero \u00c1M, Tafur-Borrero AH, Mar\u00edn-Medina DS, Acosta-Fajardo HA, Gu\u00edo-S\u00e1nchez C, L\u00f3pez-Reyes L (2024) Treatment patterns and persistence on disease modifying therapies for multiple sclerosis and its associated factors. BMC Neurol 24(1):108","journal-title":"BMC Neurol"},{"key":"13806_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/PPA.S254427","volume":"14","author":"P Tur\u010d\u00e1ni","year":"2020","unstructured":"Tur\u010d\u00e1ni P, Ma\u0161kov\u00e1 J, H\u00faska J (2020) Real-world treatment patterns of disease modifying therapy (DMT) for patients with relapse-remitting multiple sclerosis and patient satisfaction with therapy: results of the non-interventional SKARLET study in Slovakia. Patient Prefer Adherence 14:1129\u20131135","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"13806_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s13311-017-0548-5","volume":"14","author":"AL Smith","year":"2017","unstructured":"Smith AL, Cohen JA, Hua LH (2017) Therapeutic targets for multiple sclerosis: current treatment goals and future directions. Neurotherapeutics 14(4):952\u2013960","journal-title":"Neurotherapeutics"},{"issue":"6","key":"13806_CR35","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","volume":"263","author":"T Ziemssen","year":"2016","unstructured":"Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S (2016) Optimizing treatment success in multiple sclerosis. J Neurol 263(6):1053\u20131065","journal-title":"J Neurol"},{"issue":"6","key":"13806_CR36","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","volume":"271","author":"BA Singer","year":"2024","unstructured":"Singer BA, Feng J, Chiong-Rivero H (2024) Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption. J Neurol 271(6):3116\u20133130","journal-title":"J Neurol"},{"key":"13806_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000636","author":"JM Stankiewicz","year":"2020","unstructured":"Stankiewicz JM, Weiner HL (2020) An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000636","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"13806_CR38","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","volume":"18","author":"D Ontaneda","year":"2019","unstructured":"Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N (2019) Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol 18(10):973\u2013980","journal-title":"Lancet Neurol"},{"issue":"4","key":"13806_CR39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","volume":"19","author":"T Derfuss","year":"2020","unstructured":"Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L (2020) Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol 19(4):336\u2013347","journal-title":"Lancet Neurol"},{"issue":"2","key":"13806_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A et al (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2):175\u2013187","journal-title":"JAMA"},{"issue":"5","key":"13806_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, Tomassini V, Wardle M, Pickersgill T, Robertson N et al (2019) Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 76(5):536\u2013541","journal-title":"JAMA Neurol"},{"issue":"4","key":"13806_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307\u2013316","journal-title":"Lancet Neurol"},{"issue":"10","key":"13806_CR43","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, Sellebjerg F, Joensen H, Hillert J, Lycke J (2021) Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol 78(10):1197\u20131204","journal-title":"JAMA Neurol"},{"key":"13806_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106009","volume":"95","author":"D Ontaneda","year":"2020","unstructured":"Ontaneda D, Tallantyre EC, Raza PC, Planchon SM, Nakamura K, Miller D, Hersh C, Craner M, Bale C, Chaudhry B et al (2020) Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol. Contemp Clin Trials 95:106009","journal-title":"Contemp Clin Trials"},{"key":"13806_CR45","unstructured":"NCT03500328, Traditional versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS). (Accessed: October 2025) [https:\/\/clinicaltrials.gov\/study\/NCT03500328]"},{"key":"13806_CR46","doi-asserted-by":"publisher","first-page":"1274194","DOI":"10.3389\/fneur.2023.1274194","volume":"14","author":"T Spelman","year":"2023","unstructured":"Spelman T, Magyari M, Butzkueven H, Van Der Walt A, Vukusic S, Trojano M, Iaffaldano P, Hor\u00e1kov\u00e1 D, Drahota J, Pellegrini F et al (2023) Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Front Neurol 14:1274194","journal-title":"Front Neurol"},{"issue":"12","key":"13806_CR47","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1177\/1352458509348519","volume":"15","author":"IK Penner","year":"2009","unstructured":"Penner IK, Raselli C, St\u00f6cklin M, Opwis K, Kappos L, Calabrese P (2009) The fatigue scale for motor and cognitive functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 15(12):1509\u20131517","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13806-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13806-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13806-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:02:51Z","timestamp":1779451371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13806-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["13806"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13806-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.K. Penner reports speaker\u2019s bureau or advisory board and consulting fees from Adamas Pharma, Almirall, Bayer Pharma, Biogen, Celgene, Genzyme, Merck, Novartis, Roche, and Teva; and research grants from Celgene, the German MS Society, Novartis, Roche, and Teva. T. Maier, T. Wiemer, and E. Weber are employees of Roche Pharma AG. J. Leemhuis is an employee and shareholder in Roche Pharma AG. H. Schreiber reports speaker\u2019s bureau or advisory board, consulting fees, and travel reimbursement from Almirall, Biogen, Genzyme, Merck, Novartis, Roche, and Teva; research grants from Biogen, Novartis, Roche, and Teva; and membership in data monitoring or steering committees of Biogen, Novartis, and Roche. T. Ziemssen reports personal fees from Biogen, BMS, Merck, Neuraxpharm, Novartis, Novo Nordisk, Roche, Sanofi, Sandoz, Teva, and Viatris; and research support from Genzyme, Neuraxpharm, Novartis, Roche, Sanofi, and Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in accordance with the ethical principles of the 1964 Declaration of Helsinki. Approval was granted by the ethics committee of the Dresden University of Technology (EK 170042017). All patients gave their informed consent prior to their enrolment in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"292"}}